By Eric Barnes, staff writer
November 11, 2010

Tuesday, November 30 | 9:15 a.m.-9:25 a.m. | VC31-04 | Room S404CD
Distinguishing malignant from benign lung nodules using PET is tricky business, notably because not all lung cancers are glucose-avid. But in this Tuesday morning presentation, researchers from Kobe, Japan, will discuss how they found that perfusion CT on a 32-detector-row scanner and MRI both perform better than PET/CT for distinguishing malignant from benign nodules.

Yoshiharu Ohno, MD, PhD, of Kobe University, and his group examined 43 consecutive patients with 61 nodules using three modalities: 320-detector-row perfusion CT, dynamic MRI on a 1.5-tesla scanner, and integrated FDG-PET/CT.

Nodule perfusion in CT was calculated using single-input maximum slope and the Patlak-pilot methods, along with blood volume. MRI used maximum relative enhancement ratio and maximum slope of enhancement ratio. In PET/CT, maximum standardized uptake values (SUVmax) were assessed.

All but two indices showed significant differences between malignant and benign nodules (p < 0.05) at first-pass perfusion CT. Accuracies of single-input maximum slope (88.5%) and maximum slope of enhancement ratio (86.9%) at CT were significantly higher than SUVmax in PET/CT (73.8%). CT was at least as accurate as dynamic MRI and significantly more accurate than PET/CT for detecting malignant lung nodules, the team concluded.

|| About || Advertising || || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2014 || Education || Equipment Classifieds || Europe || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

Copyright © 2020 All Rights Reserved.